CLIFF (Cordlife Group) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


CLIFF Cordlife Group Ltd CLIFF
33 GF Score
Price $0.15
GF Value $0.08
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cordlife Group Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cordlife Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CLIFF vs TMO, DHR, IDXX: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Cordlife Group's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cordlife Group Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Cordlife Group's Margin of Safety % (DCF FCF Based) falls into.


CLIFF
33GF Score
Cordlife Group Ltd CLIFF
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Other Exchanges P8A:Singapore
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score

Get the complete analysis for CLIFF

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.08
GF Value